



Solid Tumor Oncology

Anatomic Pathology

Morphology
Surgical Pathology Consultation [SPC]
Surgical Pathology Professional [SPP]
Immunohistochemistry & Special Stains
Refer to A-Z listing for IHC Markers

Molecular Oncology

Next Generation Sequencing (NGS)
BRAF Mutation Analysis [M BRAF]
Colorectal Cancer NGS [M COLON NGS]
 BRAF, KRAS, NRAS
EGFR Mutation Analysis [M EGFR]
KRAS Mutation Analysis [M KRAS]

Fluorescence in situ Hybridization (FISH)

ALK 2p23 rearrangement [FP ALK]
BCL6 3q27 rearrangement [FP BCL6]
Burkitt / "Double Hit" Large B-cell Lymphoma Panel
 [FP BURKITT] [C-MYC, IGH::MYC, IGH::BCL2, BCL6]
C-MYC 8q24 rearrangement [FP CMYC]
EGFR amplification 7p11.2 [FP EGFR*]
HER2/neu Breast Cancer [FP HER2]
HER2/neu Gastric Cancer [FP HER2 GA]
IGH 14q32 rearrangement [FP IGH*]
IGH/BCL1 (CCND1) t(11;14) [FP BCL1]
IGH/BCL2 t(14;18) [FP BCL2]
IGH/MYC t(8;14) [FP IGH MYC]
IRF4 6p25 rearrangement [FP IRF4]
MALT1 18q21 rearrangement [FP MALT]
ROS1 6q22.1 rearrangement [FP ROS1]

Hematology Oncology

Anatomic Pathology

Morphology
Bone Marrow Pathology Evaluation [BMPE]
Surgical Pathology Consultation [SPC]
Surgical Pathology Professional [SPP]
Immunohistochemistry & Special Stains
Refer to A-Z listing for IHC Markers

Flow Cytometry

Flow Cytometry Leukemia / Myeloma / Lymphoma [FLOW]
Flow Cytometry Technical Only [FLOW TC]
Flow Cytometry and Morphology [FLOW M]
Bronchoalveolar Lavage [FLOW BAL]
 CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio
Leukocyte Adhesion Deficiency -CD11a, CD11b, CD11c, CD18
 [FLOW LAD*]
Paroxysmal Nocturnal Hemoglobinuria - High Sensitivity
 FLAER, CD14, CD24, CD59 [FLOW PNH]

Molecular Oncology

Next Generation Sequencing (NGS)
IgVH Somatic Hypermutation [M IgVH]
MYD88 p.L265P Mutation [M MYD88]
Myeloid Neoplasms Extended Mutation Panel [M MYELOID EXTENDED]
 JAK2 (V617F and Exon 12), CALR (Type 1 and 2), MPL, ASXL1,
 CBL, CSF3R, DUNMT3A, ETV6/TEL, EZH2, IDH1, IDH2, KIT, KRAS,
 NRAS, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1,
 ZRSR2
Polymerase Chain Reaction (PCR)
AML Mutation Analysis - FLT3, NPM1 [M AML]
B-cell Immunoglobulin Heavy Chain Gene Rearrangement [M BCELL]
BCR/ABL qRT PCR Major p210 & Minor p190 transcripts [M BCR ABL]
CEBPA Mutation [M CEBPA*]
FLT3 Mutation [M FLT3]
JAK2 V617F Mutation [M JAK2]
KIT Mutations in AML [M KIT AML]
KIT D816V Mutation [M KIT P*]
T-Cell Receptor Gamma Gene Rearrangement [M TCR]
TP53 Mutation Analysis (Exons 2-11) [M TP53]



[Hematology Oncology cont.](#)

Fluorescence in situ Hybridization (FISH)

Hematology Panels

- Acute Myeloid Leukemia Frontline Panel [F AML FRONTLINE]
[-5/5q-, -7/7q-, t(8;21), CBFβ, MLL(KMT2A)]
- Acute Myeloid Leukemia Secondary Panel [F AML SECONDARY]
[MECOM, NUP98, t(6;9), t(9;22), TP53 (17p13)]
- Burkitt / "Double Hit" Large B-cell Lymphoma Panel [F BURKITT]
[C-MYC, IGH::MYC, IGH::BCL2, BCL6]
- Chronic Lymphocytic Leukemia Panel [F CLL]
[MYB (6q23), ATM (11q22.3), +12, DLEU1 (13q14.3), TP53 (17p13)]
- Eosinophilia Panel [F EOS] [4q12, PDRGFβ, FGFR1]
- Myelodysplasia Panel [F MDS] [-5/5q-, -7/7q-, +8, 20q-]
- Myeloproliferative Neoplasms Panel [F MPD]
[+8, t(9;22), 13q-, 20q-]
- Plasma Cell Neoplasm Panel [F MM]
[1p-, 1q+, +5, +9, t(11;14), 13q-, +15, 17p-] reflex t(4;14) / t(14;16)

Hematology Probes

- AML1(RUNX1)/ETO(RUNX1) t(8;21) [F AML ETO]
- ATM/CEP11 deletion 11q22.3 [F ATM]
- BCL3 19q13.3 Rearrangement [F BCL3]
- BCL6 3q27 rearrangement [F BCL6]
- BCR/ABL1 t(9;22) [F BCR ABL]
- CBFB t(16;16), inv(16) [F CBFB]
- C-MYC 8q24 rearrangement [F CMYC]
- DEK::NUP214 t(6;9) [F DEK::NUP214]
- Deletion 7q22 [D7S796, D7S658]/7q31.2 [D7S486] [F 7q]
- Deletion 13q14.3 [F D1314]
- Deletion 20q12 [F D20]
- EGR1 5q deletion, monosomy 5 [F EGR1]
- FGFR1 8p11.2 Rearrangement [F FGFR1]
- FIPIL1/PDGFRα 4q12 gene rearrangement [F 4q12]
- IGH 14q32 rearrangement [F IGH*]
- IGH/BCL1 (CCND1) t(11;14) [F BCL1]
- IGH/BCL2 t(14;18) [F BCL2]
- IGH/FGFR3 t(4;14) [F FGFR3]
- IGH/MAF t(14;16) [F IGH MAF]
- IGH/MALT1 t(14;18) [F IGH MALT1]
- IGH/MYC t(8;14) [F IGH MYC]

- IRF4 6p25 rearrangement [F IRF4]
- MALT1 18q21 rearrangement [F MALT1]
- MECOM 3q26.2 Rearrangement [F MECOM]
- MLL (KMT2A) 11q23 Gene Rearrangement [F MLL]
- MYB 6q deletion [F MYB]
- NUP98 11p15 Rearrangement [F NUP98]
- PDGFRβ Gene Rearrangement [F PDGFRβ]
- PML/RARA t(15,17) [F PML RARA]
- PRDM16 1p36.32 Rearrangement [F PRDM16]
- TP53 17p13 deletion [F P53]
- Trisomy 8 [F T8]

Cytogenetics

- Chromosome Analysis Bone Marrow [CYTO BM]
- Chromosome Analysis Lymphoma (Lymph Node) [CYTO LN]
- Chromosome Analysis Leukemic Peripheral Blood [CYTO LPB]

Women's Health

STD and Infectious Disease

- Chlamydia Trachomatis, Qualitative by Aptima COMBO® 2 TMA [CT]
- Human Papillomavirus Genotyping [HPV G]
- Human Papillomavirus High Risk by Aptima HPV [HPV HR]
- Herpes Simplex Virus Type 1 and 2 Qualitative by PCR [HSV]
- Neisseria Gonorrhoeae Qualitative by Aptima COMBO® 2 TMA [NG]
- Trichomonas Vaginalis by Aptima [TV]

Other

Fluorescence in situ Hybridization (FISH)

- Bladder Cancer Panel [+3,+7,+17,9p21-] [F URO]

Cytogenetics

- Chromosome Analysis Peripheral Blood (Constitutional) [CYTO PB]

*Performed by affiliate laboratory